With a combined revenue of $21 trillion and $2.1 trillion in profits, the 2026 Fortune 500 is the definitive list of America's largest companies.

Fortune 500

Almost $20 trillion in revenue—and a record-breaking $1.87 trillion in profits. Introducing the 2025 Fortune 500, the definitive list of the biggest companies in America.

Industries included in the sector are electrical equipment and industrial machinery.

Fortune Sector Leaders: Industrials

The Fortune 500, in its 70th year in 2024, ranks the biggest U.S. companies by revenue.

The Fortune 500, in its 69th year in 2023, ranks the biggest U.S. companies by revenue.

Industrials came out on top this year, with 22 companies featured on the list.

100 Fastest-Growing Companies

This year’s Fortune 500 marks the 68th running of the list.

This year’s Fortune 500 marks the 67th running of the list.

This year's Fortune 500 marks the 66th running of the list.

This year's Fortune 500 marks the 65th running of the list.

This year's Fortune 500 marks the 64th running of the list.

Fastest-growing Companies

Revenue 3 Yr Growth Rank

Revenue 3 Yr Annual Growth Rate

EPS 3 Yr Growth Rank

EPS 3 Yr Annual Growth Rate

Total Return 3 Yr Rank

Total Return 3 Yr Annual Rate

Beat S&P 500 3 Yr Return

Current Streak

Years on List

Sector

Key Financials (last Fiscal Year)

Revenues ($M)

Profits ($M)

Assets ($M)

Total Stockholder Equity ($M)

Profit Ratios

Profit as % of Revenues

Profits as % of Assets

Profits as % of Stockholder Equity

Earnings Per Share (last Fiscal Year)

Earnings Per Share ($)

EPS % Change (from prior fiscal year)

EPS % Change (5 year annual rate)

EPS % Change (10 year annual rate)

Total Return

Total Return to Investors (last year)

Total Return to Investors (5 year, annualized)

Total Return to Investors (10 year, annualized)

Ingersoll Rand traces its roots to 1871, when inventor Simon Ingersoll introduced a steam-powered rock drill that helped reshape mining and construction. In parallel, Gardner Denver, founded in 1859, built a legacy in compressors and flow-control technologies. In 2020, Gardner Denver merged with the Ingersoll Rand Industrial segment to form today’s Ingersoll Rand. Today, the company is headquartered in Davidson, N.C., with roughly 21,000 employees serving customers across the globe providing mission-critical flow creation and life sciences and industrial solutions.

Q2 2026

Q1 2026

Ingersoll Rand (IR): Company Profile, Stock Price, News, Rankings

legacy

Ingersoll Rand

ingersoll rand

Hello, and welcome to the Ingersoll Rand second quarter 2026 earnings call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you would like to ask a question, please press star one on your telephone keypad. I would now like to turn the conference over to Max Borsheimer, Director of Investor Relations. You may begin.

Thank you for joining Ingersoll Rand's second quarter 2026 earnings call. I'm Max Borsheimer, Director of Investor Relations, and joining me this morning are Vicente Reynal, our Chairman and CEO, and Vik Kini, our Chief Financial Officer. Our earnings release and presentation were issued yesterday afternoon and are available on the investor relations section of our website, where a replay of this call will also be posted. Before we begin, please note that today's discussion will include forward-looking statements subject to the risks and uncertainties described in our SEC filings and on slide two of this presentation, which you should read in conjunction with the information provided on this call. We will also reference certain non-GAAP financial measures. Reconciliations to the most comparable GAAP measures are included in our earnings release and this presentation, both of which are available on the investor relations section of our website.

Today, we'll review our second quarter results, discuss segment performance, and provide an update to our full year 2026 guidance. During Q&A, please limit yourself to one question and one follow-up to allow time for other participants. With that, I'll turn the call over to Vicente.

Morning, everyone. Thank you for joining. Before we get started, I wanted to take the opportunity to formally introduce Max Borsheimer, who has added investor relations responsibilities to his current role on our M&A team. You will be seeing and hearing from him going forward, and I know he looks forward to engaging with many of you. Beginning on slide three, the second quarter and first half overall reflected continued strong execution and improved demand momentum in our business. In the second quarter, we saw organic order growth of 2%, organic revenue growth of 4%, and adjusted EPS growth of 7%, demonstrating the strength and resiliency of our business. Our growth this quarter was broad-based across our diversified end market base. Every main region this quarter delivered positive organic revenue growth, and we continue to focus investments towards durable, structurally growing end markets.

Importantly, our first half performance and the healthy demand trends we continue to see across much of the business reinforce our confidence in our outlook for the remainder of the year. As we will walk you through this morning, we are raising our full-year revenue guidance and expect adjusted EPS to land towards the higher end of our previously communicated range. We also remain disciplined in our approach to capital allocation. Our acquisition pipeline continues to be robust, including two new announcements today, and remains focused on targeted bolt-on opportunities that strengthen our core technologies, expand our aftermarket presence, and enhance our long-term growth profile. Our teams around the world remain focused on controlling what we can control. Through the use of IRX and our economic growth engine, we continue to drive operational execution, support our customers, and outperform in the markets we serve.

Turning to slide four, before moving to our operational and financial results, I would like to briefly acknowledge the continued recognition we have received for our sustainability leadership and employee ownership culture. During the last year, we were recognized across multiple leading ESG, workplace, and corporate citizenship rankings, including joining the 2026 Fortune 500, a milestone that reflects the scale, discipline, and momentum we have built as the Ingersoll Rand we are today. These recognitions, further outlined in our recently published sustainability report, reflect the strength of our ownership mindset culture and our commitment to making life better for our employees, our customers, our shareholders, and our planet. Turning to slide five. I am excited today to announce the closing of one acquisition and the signing of another.

Just this morning, we closed on the acquisition of Lone Star Blower, the company referenced as a U.S.-based blower manufacturer in the presentation. Lone Star Blower expands our expertise in key blower technologies and solutions and expands our aftermarket presence through an established service business and rental fleet. This acquisition will add approximately $50 million in annual revenue. We are also excited to announce the signing of the acquisition of Fai Filtri, a manufacturer of industrial filters based in Italy. This acquisition will expand our filtration capabilities and also strengthen our aftermarket offerings. We expect this acquisition to close in Q4 and add approximately $30 million in annual revenue. Both of these transactions are highly consistent with our strategy of acquiring market-leading technologies that strengthen our core while maintaining disciplined valuation standards.

Notably, both acquisitions strengthen our aftermarket capabilities, a key focus area as we continue to increase the resiliency and recurring revenue characteristics of our portfolio. We have 11 additional transactions under LOI, and our funnel remains strong, focused on proprietary and internally sourced deals. Our disciplined M&A strategy remains a key differentiator and continues to be an important driver for long-term value creation. Now, I will hand it over to Vik, who will review our financial performance.

Thanks, Vicente. Starting on slide six, the second quarter represented another solid quarter of execution. Orders finished just over $2 billion, up 5% year-over-year, with organic orders up 2%. Book-to-bill finished at 1.0 turns, slightly lower than we typically see in the second quarter, primarily reflecting the delayed timing of several large project orders. Important to note that we continue to see solid momentum in our short to medium cycle business, where orders were up mid-single digits. In addition, we expect these longer cycle projects to recover in the back half of the year, and Vicente will provide some color on what we have seen thus far through July. Revenue grew 9% year-over-year to approximately $2 billion, with organic revenue growth of 4%. Aftermarket revenue represented 36% of total revenue during the quarter and continues to be an important contributor of the resiliency of our portfolio.

Adjusted EBITDA was $520 million, an increase of 2% year-over-year, with an adjusted EBITDA margin of 25.4%. Adjusted EBITDA margin was down 160 basis points year-over-year, with the decline driven primarily by three factors. First, inflationary pressures, particularly in China, where it is more challenging to offset inflation with price. Second, continued investments to support growth around new technology and commercial applications, and third, higher corporate costs. The higher corporate costs were largely driven by year-to-date true-up of management incentive costs reflecting incentive compensation adjustments aligned with performance, which we do not expect to recur at this level in the back half of the year. Unallocated corporate costs were $49 million in the quarter versus $34.6 million a year ago, driven largely by the incentive true-up, and we continue to expect approximately $170 million in corporate costs for the full year.

Despite this quarter's year-over-year margin rate pressures, we remain confident in our ability to deliver within our previously communicated adjusted EBITDA range through continued operational execution and productivity actions. In terms of the sequential margin expansion we expect to see in the second half of the year, the margin ramp in the back half of the year is normal course for us, as first half pricing actions and benefits from first half productivity projects are realized. We also had the incentive comp true-up here in second quarter that we do not expect to repeat to the same magnitude in the back half of the year. Adjusted EPS was $0.86 for the quarter, up 7% year-over-year. Turning to slide seven, free cash flow for the quarter was $269 million, up roughly 28% year-over-year.

We ended the quarter with approximately $3.8 billion of total available liquidity, including approximately $1.2 billion of cash and $2.6 billion of available revolving credit facility capacity. Leverage remained at 1.7x, providing significant balance sheet flexibility. During the quarter, we deployed $110 million towards acquisitions and returned approximately $248 million to shareholders through share repurchases and dividends. We were also pleased to receive a one-notch upgrade from Moody's to Baa1 during the quarter, further reinforcing the strength of our balance sheet and capital allocation strategy. Overall, our balance sheet remains a strategic asset and positions us well to continue investing in attractive growth opportunities.

One other update I wanted to provide here, as you will see disclosed in our 10-Q for the second quarter, we reached an agreement on an initial $187.5 million recovery with certain insurers on the RWI claim that we filed last year related to the ILC Dover transaction. We collected the first $25 million in the second quarter, and this is reflected in the free cash flow for the quarter, with the remaining $162.5 million to be received during 2026. This is a significant and favorable initial recovery, and we continue to actively pursue additional meaningful recoveries related to the ILC Dover transaction beyond the $187.5 million. Consistent with our focus on earnings quality, these recoveries are excluded from adjusted earnings, and the incremental cash that we expect to collect in the second half of 2026 is not reflected in our free cash flow guidance.

We therefore view it as pure upside that directly strengthens our capital allocation firepower. I'll now turn the call back to Vicente to discuss our segment performance.

Thanks, Vik. Turning to slide eight, ITS deliver another solid quarter. Revenue increased nearly 9% year-over-year, including organic revenue growth of 4%. Organic revenue growth was positive across all regions. Orders were approximately flat organically, resulting in a book-to-bill ratio of one time. Within our compressor business, we continue to see healthy activity, particularly in North America, where organic orders were up high single digits. Overall compressor orders increased by low single digits globally. Organic order growth was impacted by the timing of several long-cycle blower and vacuum projects in Europe, as well as the continuing impact on the Middle East, where specific project activity remains delayed rather than canceled. ITS generated adjusted EBITDA of $435 million with margins of 26.8%.

Margin performance was impacted primarily by challenges offsetting inflationary impacts with price, primarily in China, and continued commercial investments to support future growth. For our innovation in action highlight, we're showcasing a plug-and-play on-site nitrogen generation solution that integrates multiple products from our portfolio into a single factory-tested system. The solution enables faster deployment, simplified commissioning, and full lifecycle support, demonstrating our ability to leverage the breadth of our technology portfolio to solve critical customer needs. This solution also demonstrates the commercial synergies we continue to realize through M&A. The system combines technologies from our Oxywise, Gardner Denver, and York brands into a single integrated solution for customers. Turning to slide nine, PST delivered an excellent quarter and continues to demonstrate the strength of the platform we have built. Orders increased 11% year-over-year, including 7% organic growth.

Life sciences delivered low double-digit organic order growth, while precision technologies grew mid-single digits organically. Revenue increased by 8% year-over-year, including 4% organic growth. Importantly, both life sciences and precision technologies delivered positive organic revenue growth in the quarter. Adjusted EBITDA increased 15% year-over-year to $135 million. Adjusted EBITDA margin expanded 200 basis points year-over-year to 31.5%, reflecting strong execution across the portfolio and the continued benefits of IRX. We're encouraged by the breadth of growth we're seeing across the segment and remain excited about the long-term opportunities within both life science and precision technologies. For our innovation in action, we're showcasing Dosatron's installation-ready dosing systems. This standardized solution simplify deployment, improve reliability, and reduce installation complexity for customers while supporting strong commercial momentum across the business.

I'm also proud to share that following the significant earthquake that recently struck the Philippines, Ingersoll Rand partnered with Planet Water Foundation to deploy safe drinking water stations across the hardest hit areas. Planet Water Foundation is not only a partner but also a valued Dosatron customer, as our pumps are a key component of the AquaBlok kiosks that deliver safe drinking water in these situations without the need for electricity. It serves a good reminder of the mission-critical nature of our portfolio and an example of our purpose of making life better in action. Turning to slide 10, given our momentum through the first half of the year, today we are updating our full year guidance.

Starting with revenue, we now expect revenue growth of 4.5%-6.5%, 200 basis points higher at the midpoint, driven primarily by organic volume, reflecting a strong first half and healthy demand, particularly in the short to medium cycle side of the business. This outlook assumes approximately 1%-3% organic growth, approximately 2.5% growth from M&A, and approximately 1% growth from FX. We're maintaining our adjusted EBITDA guidance range of $2.13 billion-$2.19 billion. As Vik mentioned, the margin ramp we see in the second half is largely driven by first half pricing actions taking effect, the non-recurrence of the incentive compensation true-up in Q2, and benefits from stronger productivity in the back half of the year from projects executed in the first half, all of which is normal course and consistent with prior years.

Adjusted EPS remains projected at $3.45-$3.57, and based on our current expectations, we expect results to finish near the high end of the range. Free cash flow conversion is currently expected to remain approximately 95%. The phasing of revenue, adjusted EBITDA, and adjusted EPS remains consistent with prior years. One additional clarification on our guidance is that our adjusted EBITDA and adjusted EPS ranges exclude any benefit from IEEPA tariff refunds we expect in the second half of the year, which we will view as upside. We will update guidance once those amounts are materially received. To give a bit of color on our start to Q3, while we don't guide on orders, I am happy to share that we have had a great start to July, where we have seen double-digit order growth through the first four weeks of the month.

We have seen strong realization of several long cycle orders, which were delayed in the first half across all of our main regions, along with continuation of the short to medium cycle strength that Vik mentioned earlier. We're encouraged in what we're seeing, and we're confident in achieving our updated guidance for the remainder of the year. Finally, on slide 11, as we conclude this portion of the call, I am encouraged by the momentum we continue to see across the business. Demand remains healthy across the portfolio. Our teams continue to execute at a high level, and our M&A pipeline remains robust. We remain well-positioned with a strong balance sheet, ample liquidity, and significant flexibility to continue investing in growth. IRX remains the backbone of our organization and continues to enable execution and outperformance across the company.

As we look ahead in the second half of the year, we believe we're well positioned to continue to deliver durable growth, strong cash flow generation, and long-term value creation for our shareholders. Finally, and more important, I want to thank our employees around the world for their continued commitment, dedication, and ownership mindset. Your efforts continue to drive our success and help us deliver strong results for all stakeholders. With that, I'll turn the call back to the operator and open the line for questions.

Thank you. If you would like to ask a question, please press star one on your telephone keypad. If you would like to withdraw your question, simply press star one again. As a reminder, we ask that you please limit yourself to one question and one follow-up. Thank you. Your first question comes from Michael Halloran with Baird. Your line is open.

Hey, thank you. Morning, everyone, and welcome, Max.

Can we talk a little bit about the momentum you're seeing on the short and medium side of things now? Maybe just drill in a little bit more on regional dynamics and any end markets in particular that you're seeing that momentum. It seems like you're pretty comfortable that that momentum can sustain as we're exiting the second quarter through July and onward, any thoughts on how that momentum phases out?

Yeah, Mike, let me first give you by region. Americas is roughly 50% of our revenue, and it's been the strongest region so far. ITS orders up high single digits, healthy compressor activity. We're seeing the short cycle indicators that are the best in the portfolio. EMEA is about a third of the revenue. Orders were down low double digits organically, and I want to be precise about why. It is two things, both timing rather than demand, is the phasing of some long cycle projects orders in our blower and vacuum side of the business in Europe, and it's also the Middle East. Underneath that, core compressor orders in the region were up low single digits organically, which is better read on the underlying market. Asia Pacific, which is about 15%, with China around 10% of total.

China organic revenue was up low double digits in the quarter. The volume story there is very good, but as we indicated in the prepared remarks, this continues to be the most challenged market from a pricing perspective. We're encouraged by how our original equipment is getting into the market again in China, for China, in some very kind of unique applications that we expect will generate some very good aftermarket in future years. From end market perspective, PST, we mentioned life sciences, obviously up mid-teens, driven mainly in this case here biopharma. Biopharma we continue to see that low double-digit growth there, and very encouraged about the timing of bringing the full Ingersoll Rand portfolio into biopharma. Not just what we get in PST, but now the team is driving pull-through of other technology into biopharma. In the ITS, it's broad-based.

I mean, Americas, we saw momentum in power gen, electricity infrastructure, some air separation for semiconductor. Europe is resiliency, continues in general industrial, food, beverage, kind of the more normal industrial side. We still expect maybe defense picking up here soon, hopefully. Asia Pacific is growing in kind of electronics, shipbuilding, among others. You can see kind of multiple, fairly broad-based in many cases.

No, that makes sense. Maybe just on the larger projects, I know you referenced some of it there, the longer cycle projects. Are you at the point where project pushouts are starting to roll through and people are willing to move forward with projects? Are we still seeing delays on a global basis, and how do you think that long cycle activity plays out as we look forward?

I think, Mike, that's where we are getting more and more encouraged. For a while, we were talking about this elongation and kind of what we're seeing now is basically customers getting more enthusiastic and projects getting kind of moved in a better direction. We're seeing better momentum on the long cycle projects, yes.

Your next question comes from Jeff Sprague with Vertical Research. Your line is open.

Just a quick follow-up on the long cycle. Is there any sort of common thread in what is now being released and previously held up and released, perhaps more energy or some other vertical market? Any real common thread you'd point to there?

Jeff, good point. This is actually one of the more encouraging conversations we're having in terms of that energy efficiency. As you know, being compressed air is typically 30% of the industrial electricity consumption in a manufacturing facility, and it could be higher based on application. We're seeing more, as power prices have moved up, the payback on replacing an older, less efficient machine, it's getting shorter. Definitely that is definitely one of the key indicators here that we're seeing that is driving some better momentum, among other things. I think historically, past few earnings calls, we were talking about kind of delays in project just due to engineering capacity, or it could be EPC, a lot of that is also kind of freeing up too as well.

Great. Maybe just a quick one for Vik also. Just on the organic revenue guide, is this primarily a reflection of going after additional price, or is there actually some improved volume sort of underpinning that bump? Where would the volume improvement be if there is some?

Yeah. Jeff, I think it's more the latter. It's the volumes, the organic volumes. I think as we indicated in the prepared comments here, encouraged by what we saw in Q2, where you saw 4% overall organic growth. I think, volume was obviously relatively healthy there, particularly on the short and medium cycle side of the business. I think that's where you're really seeing the uptick. The incremental 1% organic for the full year is really volume driven. I think as Vicente said here, encouraged by what we're seeing both on the Americas front, China continues to show good momentum there. That's really where we're seeing it. Price, we have taken certain pricing actions in the first half of the year, which was consistent with our expectations. Those are starting to more materialize into the back half of the year.

I would say that's fairly consistent with what we had expected in previous guidance.

Okay, great. I'll leave it there. Thanks.

Your next question comes from Nigel Coe with Wolfe Research. Your line is open.

Good morning, guys. Max, I look forward to meeting you in due course. Just on the orders in July, obviously really encouraging to see that those longer cycle orders starting to kick in. Can I just clarify, when you say double digits, so if we strip out acquisitions, et cetera, we're still seeing double digit organic orders? Just want to clarify that one, first of all. Are we seeing the backlog building for 2027, given that these are longer cycle projects, or could these hit in the back half of the year? It doesn't feel like you're baking these orders into the back half of the year.

Yeah, Nigel, let me take the first one and let Vik comment about the second one. Yes, organic is low double digit to mid-teens, basically, is what we're seeing here in the month of July.

Nigel, just to follow up on that. As far as the long cycle projects, definitely building the backlog out for 2027. As you would expect, most of these are long cycle projects or the typical 6-18 month type duration in terms of projects typical to what you've seen. They're largely building out the backlog for 2027. That's not to say that some won't have some revenue recognition here in the back half of the year, yes, solid backlog build more as we move into 2027 with regards to some of those longer cycle projects.

That's great. Just maybe just a bit more details on the ITS margin momentum through the back half of the year. Can you just maybe just clarify, was the sort of the margin weakness in the quarter, was that confined to China, and the price pressure in China, or was it a bit broader than that?

No, Nigel, it's really confined to China, basically. In addition to some of the investments that we're making. You saw we made an announcement earlier in the quarter about a partnership that we made for some new technology too as well. It continues to be some good investments that we're doing, despite what kind of market conditions might be. In top of that has been the pricing on challenge in China.

Your next question comes from Rob Wertheimer with Melius Research. Your line is open.

Yeah, thanks. Good morning. I wanted to check in on trends in life sciences and PST. It seems like you had pretty good orders. Comp was a little bit easy, there were some kind of cross currents around the industry that don't seem to have affected you in the quarter. I wonder if you could just sort of characterize the market. Is it steadily rolling? Is it accelerating? How do you see it right now? Thank you.

Yeah. Hey, Rob. We see good momentum on the life science business as we kind of alluded here. We see that is largely driven by the biopharma. In our case, the exposure that we continue to have to GLP-1 is very strong. As that market continues to grow and seeing some investments, we're pleased to see that. In addition, we have made some investments to play in the larger biopharma side, are working on what you also kind of hear in the news on the biopharma expansion. A lot of that hasn't come to fruition yet, we're excited about what the potential of that could be as we move into the second half or even 2027, based on the new facilities that are kind of getting invested now.

Again, we see continued stability in that market and good growth, based on, again, the investments that we're making and the focus that we're putting in to really accelerate our penetration in the biopharma side.

Your next question comes from Nathan Jones with Stifel. Your line is open.

I guess I'll ask the same question I ask on most of these calls, Vicente, about quote-to-order times. Obviously, you had a few of these longer cycle projects get delayed in the quarter, but if you kind of exclude those, are you seeing any changes in that quote-to-order time? Maybe in the U.S. you are, maybe in Europe you're not, but any details you could give us on, I guess, the customer's willingness to accelerate these orders?

I would say, Nathan, nothing dramatically significant. Obviously, you're seeing the short cycle business, and Vik mentioned that. Mid-single digit organic order growth on 10-hour short cycle business. We continue to see momentum, and when we see EBITDA sequentially continue to improve, and obviously now here in July as well. In terms of that quote-to-order, I don't think anything that customers are trying, at least not on our products or the end markets where we play, that we have seen that customer quote-to-order cycle get shortened dramatically.

Okay, fair enough. Maybe just a question on China and the pricing power over there. Ingersoll Rand has always tended to try and play in areas and products where it has significant differentiation and can command price. Are there opportunities here for you to consider what you want to sell in China, how you want to sell it and look at the portfolio overall through that kind of lens where, maybe some of these products you're selling in China don't have pricing power and you don't need to be in that business? Or anything from that perspective?

Sure. Nathan, I would say we're always going to play mission-critical products where total cost is low based on the total process in the equation. Right now what you see in China is just basically a timing issue in our view. More broadly, we're spending quite a bit of time localizing newly acquired technologies into China, and typically under an existing brand that we have in China. I wouldn't say that we're cutting back on our product portfolio, but rather investing in new technologies in the market where we have seen success from acquired businesses elsewhere and have unique technology that we can have. The second big piece is that a lot of the growth that we see in China is related to original equipment, whole goods, which comes at a lower margin typically than the aftermarket.

In some cases, what we have done here in China, as there have been some very unique applications with specific customers that we never had before, but that we see that can have a great potential in the future for us, we're making some commercial investments to really penetrate those new applications. Again, in China for China. I say we feel good about the product portfolio we have in China, and we continue to invest in China for China.

Okay, the pricing is a bit more transient an issue.

Your next question comes from Andy Kaplowitz with Citigroup. Your line is open.

Vicente, it looks like you've continued to have nice acceleration in your Precision Technologies business. Could you talk about the durability of that growth? What are the biggest drivers? I think Precision is mostly comprised of shorter cycle markets, so is it fair to expect continued acceleration from that mid-single-digit growth from here?

Yeah, Andy, I think we're very pleased with what we're seeing on the PST side. As you remember, even going back to our last investor day, we said that this segment should be in kind of that mid-30 EBITDA. Not just a mid-single digit grower organically, and we're getting back to that. Again, great progress that we're seeing here on the growth, but also on the margin expansion.

Yeah. Andy, on the specific to the Precision Technology side, we would agree. You're seeing solid momentum. That business has a comparable look and feel in some respects to ITS. Yes, you have seen good continued momentum on what I'll call some of the shorter cycle kind of core pump businesses. There is longer cycle project activity there as well, and I think we're working through that just like you'd see on the ITS side. I'd say fairly comparable trends specifically on the Precision Technology side as to kind of what you've seen on the ITS side.

Great. On M&A, Vicente, you raised your contribution to two and a half for 2026 from closed deals, which I think puts you right on target for your usual algorithm. You had a couple of nice announcements today. I look back at the last few years, you've tended to be a little further along at this point in the year. How would you characterize the M&A environment in general this year versus past years?

I would say very healthy. Our funnel is very healthy, over 200 companies that we have in the funnel. No difference. Right now, so far, including these transactions that we announced today, we're kind of halfway point to the commitment of the annualized acquire. I think we're making some good progress, and I think it's difficult to compare the cadence of deal activity each year against another. We're excited where we are. We got great prospects. You learn transactions on the LOI and healthy activity, and with a very good discipline pre-synergy multiple.

Your next question comes from Joe Ritchie of Goldman Sachs. Your line is open.

Hey. ITS, I'm curious, would your margins have expanded this quarter, absent the China headwind that you guys described? Also, as you think about the year, is your expectation that you can kind of still hold margins kind of like flattish, with where ITS margins were a year-ago?

Yeah, Joe, I'll take that in two pieces here. The first part here, China was without question the biggest piece, obviously. I would say it would've been much more comparable is probably the best way to say it. That's not obviously the only moving factor, but that is without question the single biggest driver for the factors that Vicente indicated with regards to much more the pricing side, comparatively speaking to some of the inflationary headwinds. As far as on the full year and what the guide implies into the back half, I think as we exit the year, particularly in the fourth quarter, I think you're much more in line with prior year and actually probably even slightly above the exit rates we had for the prior year.

I would say on a full year basis, it's still probably trending a little bit below on a full year basis, comparatively speaking, to where we were in full year 2025. Again, I think we view that, as Vicente said, a lot more timing-oriented here. I think with the momentum we continue to see, particularly on the organic volume front as we exit the year, as well as some of the China items that we view as a bit more transient, for lack of a better way to say it. We don't see any reason why the ITS business can't continue to have that earnings power approaching that 30% EBITDA margin profile consistent with what we've talked about in our prior investor days.

Got it. That's clear, Vik. Thank you. Vicente, just touching on those longer cycle orders from July, I'm curious, and maybe I didn't hear it, but from an end market standpoint, does a particular end market stand out to you on what's converting into orders? Then as you think about your pipeline for the rest of the year, how does that large project pipeline look?

Yeah, Joe, I say nothing that I will say one specific end market focus. It's kind of becoming a very nicely broad-based food, beverage, pharma, power gen, air separation for semiconductors. It's actually a very good blend on multiple end markets, which we like. As we think about the rest of the year in terms of the pipeline, very consistent with that. Consistent with having a good blend of multiple end markets in the long cycle.

Your next question comes from Chris Snyder with Morgan Stanley. Your line is open.

Thank you. At least on my math, it seems like this back half margin ramp off of that Q2 base is a bit stronger, at least on the higher end of what you guys typically deliver. It seems like a lot of that is driven by this price cost catch-up. I guess could you just maybe kind of talk about the drivers of that sequential margin expansion off Q2? Since it seems like it's mostly driven on price, any color on just how much incremental price is coming into the back half following some of the actions you guys took, I guess, in Q2? Thank you.

Yeah, Chris, I'll bucketize it to keep it simple here, maybe into three major drivers here. First and foremost, in line with what you said, there is, I would say, better price realization just in the context of some of the actions that we took through the first half of the year and executed in the second quarter. Again, I would say that's a third of it. A third, to kind of repeat, on an enterprise-wide basis, obviously corporate, we expect to be a bit more normalized into the back half of the year. Clearly, we had the incentive compensation true-up that we took in Q2 that we don't expect to repeat at the same level in the back half.

The balance is what I would say is somewhat, generally normal course here, is the expectation on the productivity and to some degree, some of the mix you would expect to see coming into the back half of the year. As a reminder, we typically see a lot more of our productivity benefits from actions taken, whether it be on the classical direct material or I2V side, as well as, to repeat, some of the restructuring actions we took towards the end of last year into the beginning of this year materialize more into the back half of the year. Remember that direct material productivity generally follows our cost of goods sold. In particular, as you typically have your strongest finish towards the fourth quarter, that's where you tend to see a lot of that come through.

I'd say those are probably the three biggest drivers.

Thank you, Vik. I really appreciate that. Maybe tying that to the July order comment, which was obviously a really strong inflection for you guys on the long cycle side. I just want to confirm, it seems like this order inflection came after you guys put price in, which is more constructive than seeing the order inflection, of course, before the price action. If you could confirm that. Thank you.

Yeah, I think, Chris, that's a fair point here. The way I would probably think about it is, remember, a lot of these longer cycle projects that are booking through here in July, they've been in the funnel for some time. These have been active dialogue, negotiations, things of that nature. Yes, it's great to see them now get to the finish line, for lack of a better way to say this. I wouldn't also lose track of the fact that in the midst of July, we're also seeing, I'd say, continued solid short cycle momentum. I think your comment is quite fair. Yes, the long cycle is probably the biggest driver of that number you're seeing in July, but that's not coming without some good contribution also from the short cycle side as well.

Your next question comes from Amit Mehrotra with UBS. Your line is open.

I guess just following up on the July commentary, because I want to make sure that the market's expectations are correct. It really comes down to the attribution of these long cycle projects. Maybe there are a few of them, but is the positive implication of that disclosure that this is kind of the trend that we can build on or sustain? Or is it really a data point that's idiosyncratic to maybe a couple of projects that hit in July? I don't want to be here in August, September saying we're back to low single digits because of that dynamic. Maybe you can give us a little bit of color on that.

Ingersoll Rand (IR) Q2 2026 Earnings Call Transcript

Company Participants